Sales volume of the final dosage forms of Grindeks in the first six months of 2015 was 39.4 million euros and has increased by 4.9 million euros or 14% in comparison to the first six months of 2014. The sales amount in Russia, other CIS countries and Georgia reached 23.6 million euros in the first six months of 2015, which is by 5.3 million euros or 18% less than in the first half year of 2014. In comparison to the first six months of the previous year the biggest increase in sales volumes has been reached in Armenia (18%), Georgia (27%), Kirgizstan (28%) and Turkmenistan (26%). In the first six months of 2015 Grindeks has complemented its range of products and introduced the final dosage form (capsule) of Ursodeoxycholic acid (UDCA) and started its export to Russia and Georgia. Thereby Grindeks has widended its offer in the gastrointestinal tract and metabolism drug therapeutic group.

Thanks to successful business diversification and the development of company’s activities in new markets, turnover of the final dosage forms in the Baltic States and other countries amounted to 15.9 million euros, which is by 10.2 million euros or 2.8 times more than in the first six months of 2014. The sales volume in Poland in comparison with first six months of 2014 has increased 6.4 times, while in Vietnam 2.6 times. The sales volume in Latvia in the first six months of this year accounted to 3.1 million euros and has increased by 1.3 million euros or 72% comparing with the first six months of last year.

In the first half year of 2015, sales of the active pharmaceutical ingredients reached 4.1 million euros, which is by 2.0 million euros or 33% less than in the first half year of 2014. Main markets of Grindeks active pharmaceutical ingredients are the EU countries, USA, Canada and Japan. The most required active pharmaceutical ingredients of Grindeks in the first half year of 2015 were Oxytocin, Zopiclone, Xylazine, Medetomidine and Pimobendan.

The Chairman of the Board Mr. Juris Bundulis: “Current events and changes in the global economy are strongly influencing Latvian exporters, including the joint stock company «Grindeks». Step by step our implemented business diversification is bringing positive results, therefore I am pleased with Grindeks’s performance in Vietnam, Poland and other countries outside company’s usual markets. Deeply committed we will continue to make investments in the development of new markets. For all that, to reduce the business risks as well as improve our operations, we are still going to pay great attention to CIS countries.”

Grindeks unaudited financial statements 2015 Q2 (413 KB)